Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles

International Journal of Pharmaceutics

Volumn 436, Issue 1-2, 2012, Pages 798-805

  Silva, A C ^a,b   Kumar, A ^c   Wild, W ^c   Ferreira, D ^a   Santos, D ^a   Forbes, B ^c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Biocompatibility; Caco 2 cells; Oral delivery; Risperidone; Solid lipid nanoparticles

Indexed keywords

GLYCEROL BEHENATE; RISPERIDONE; SOLID LIPID NANOPARTICLE;

ARTICLE; BIOCOMPATIBILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSPORT; IN VITRO STUDY; IN VIVO STUDY; OXIDATION REDUCTION POTENTIAL; PHARMACOLOGICAL PARAMETERS; POLYDISPERSITY INDEX; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; CACO-2 CELLS; CELL SURVIVAL; DRUG CARRIERS; DRUG STABILITY; HUMANS; LIPIDS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; PRESSURE; RISPERIDONE; SOLUBILITY;

EID: 84865733382     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.07.058     Document Type: Article

References (40)

1. M.R. Alex, A.J. Chacko, S. Jose, and E.B. Souto Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting Eur. J. Pharm. Sci. 42 2011 11 18
2. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
3. J. Araujo, E. Gonzalez-Mira, M.A. Egea, M.L. Garcia, and E.B. Souto Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications Int. J. Pharm. 393 2010 167 175
4. N.H. Bhanji, G. Chouinard, and H.C. Margolese A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia Eur. Neuropsychopharmacol. 14 2004 87 92
5. S. Chakraborty, D. Shukla, and S. Singh Lipid - an emerging platform for oral delivery of drugs with poor bioavailability Eur. J. Pharm. Biopharm. 73 2009 1 15
6. P. Costa, and J.M. Lobo Modeling and comparison of dissolution profiles Eur. J. Pharm. Sci. 13 2001 123 133
7. S. Das, and A. Chaudhury Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery AAPS PharmSciTech. 12 2011 62 76
8. S. Das, W.K. Ng, P. Kanaujia, S. Kim, and R.B. Tan Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables Colloids Surf. B: Biointerfaces 88 2011 483 489
9. S.R. Deshiikan, and K.D. Papadopoulos Modified Booth equation for the calculation of zeta potential Colloid Polym. Sci. 276 1998 117 124
10. J.B. Dressman, and C. Reppas In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs Eur. J. Pharm. Sci. 11 2000 S73 S80
11. R. Duncan, and R. Gaspar Nanomedicine(s) under the microscope Mol. Pharm. 8 2011 2101 2141
12. A.T. Florence Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov. Today: Technol. 2 2005 75 81
13. ®.
14. L. Jia Nanoparticle formulation increases oral bioavailability of poorly soluble drugs: approaches experimental evidences and theory Curr. Nanosci. 1 2005 237 243
15. J. Kuntsche, J.C. Horst, and H. Bunjes Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems Int. J. Pharm. 417 2011 120 137
16. K. Lang, J.L. Meyers, J.R. Korn, S. Lee, M. Sikirica, C. Crivera, R. Dirani, and J. Menzin Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics Psychiatr. Serv. 61 2010 1239 1247
17. N. Lewinski, and V. Colvin Cytotoxicity of nanoparticles Small 4 2008 26 49
18. W. Mehnert, and K. Mader Solid lipid nanoparticles: production, characterization and applications Adv. Drug Deliv. Rev. 47 2001 165 196
19. V. Meunier, M. Bourrie, Y. Berger, and G. Fabre The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications Cell Biol. Toxicol. 11 1995 187 194
20. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63
21. M. Muchow, P. Maincent, and R.H. Müller Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery Drug Dev. Ind. Pharm. 34 2008 1394 1405
22. R.H. Müller, K. Mäder, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177
23. R.H. Müller, W. Mehnert, J.S. Lucks, C. Schwarz, A. zur Muhlen, H. Weyhers, C. Freitas, and D. Ruhl Solid lipid nanoparticles (SLN) - an alternative colloidal carrier system for controlled drug delivery Eur. J. Pharm. Biopharm. 41 1995 62 69
24. R.H. Müller, R. Shegokar, and C.M. Keck 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications Curr. Drug Discov. Technol. 8 2011 207 227
25. C.M. O'Driscoll, and B.T. Griffin Biopharmaceutical challenges associated with drugs with low aqueous solubility - the potential impact of lipid-based formulations Adv. Drug Deliv. Rev. 60 2008 617 624
26. G. Oberdorster Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology J. Int. Med. 267 2010 89 105
27. N. Patel, B. Forbes, S. Eskola, and J. Murray Use of simulated intestinal fluids with Caco-2 cells and rat ileum Drug Dev. Ind. Pharm. 32 2006 151 161
28. C.J. Porter, K.M. Wasan, and P. Constantinides Lipid-based systems for the enhanced delivery of poorly water soluble drugs Adv. Drug Deliv. Rev. 60 2008 615 616
29. C.W. Pouton Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system Eur. J. Pharm. Sci. 29 2006 278 287
30. P.L. Ritger, and N.A. Peppas A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs J. Control. Release 5 1987 23 36
31. P.L. Ritger, and N.A. Peppas A simple equation for description of solute release II. Fickian and anomalous release from swellable devices J. Control. Release 5 1987 37 42
32. R.A. Rosenheck, J.H. Krystal, R. Lew, P.G. Barnett, L. Fiore, D. Valley, S.S. Thwin, J.E. Vertrees, and M.H. Liang Long-acting risperidone and oral antipsychotics in unstable schizophrenia N. Engl. J. Med. 364 2011 842 851
33. A.C. Silva, E. Gonzalez-Mira, M.L. Garcia, M.A. Egea, J. Fonseca, R. Silva, D. Santos, E.B. Souto, and D. Ferreira Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound Colloids Surf. B: Biointerfaces 86 2011 158 165
34. A.C. Silva, C.M. Lopes, J. Fonseca, M.E. Soares, D. Santos, E.B. Souto, and D. Ferreira Risperidone release from solid lipid nanoparticles (SLN): validated HPLC method and modelling kinetic profile Curr. Pharm. Anal. 8 2012 1 10
35. Silva, A.C.; Santos, D.; Ferreira, D.; Lopes, C.M.; 2012. Lipid-based nanocarriers as an alternative for oral delivery of poorly water-soluble drugs: peroral and mucosal routes. Curr. Med. Chem.; accepted.
36. E.B. Souto, P. Martins-Lopes, C.M. Lopes, I. Gaivao, A.M. Silva, and H. Guedes-Pinto A note on regulatory concerns and toxicity assessment in lipid-based delivery systems (LDS) J. Biomed. Nanotechnol. 5 2009 317 322
37. ® 888 ATO as bulk lipid and as SLN and NLC J. Microencapsul. 23 2006 417 433
38. E.B. Souto, and R.H. Müller Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes Handb. Exp. Pharmacol. 197 2010 115 141
39. R.B. van Breemen, and Y. Li Caco-2 cell permeability assays to measure drug absorption Expert. Opin. Drug Metab. Toxicol. 1 2005 175 185
40. L. Wu, J. Zhang, and W. Watanabe Physical and chemical stability of drug nanoparticles Adv. Drug. Deliv. Rev. 63 2011 456 469